Design of a phase 3, randomized, double-blind, placebo-controlled, 48-week study to evaluate the efficacy and safety of cendakimab in adult and adolescent patients with eosinophilic esophagitis
This phase 3 pivotal study will determine whether cendakimab provides an effective, safe, targeted treatment for patients with EoE.
Authors
- Evan S. Dellon (ORCID: https://orcid.org/0000-0003-1167-1101)
- Ikuo Hirano (ORCID: https://orcid.org/0000-0001-7688-9377)
- Alain Schoepfer
- Christina M. Charriez
- Young S. Oh (ORCID: https://orcid.org/0000-0001-5445-2860)
- Sandra Zhang
- Vrunda Patel
- Claudia H M C de Oliveira
Institutions
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- Centre Hospitalier Universitaire Vaudois (CH)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Sweden) (SE)
- University of Lausanne (CH)
Publication Details
- Journal
- Contemporary Clinical Trials
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1016/j.cct.2024.107708
- Citations
- 4
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 2.29
Funders
- Bristol-Myers Squibb